Mabion (MAB) Company presentation summary

Company overview and strategy

• Operates as a biologics-focused CDMO with 18 years of experience in developing and manufacturing biological medicines, including monoclonal antibodies and recombinant proteins.

• Offers comprehensive CDMO services, including sterile manufacturing, packaging, serialization, and bioanalytical capabilities, with a strong quality management system (GMP and ISO certified).

• Implementing a 2025-2030 strategy focused on technology, operational excellence, and portfolio diversification, aiming to become a leading, profitable, and scalable Drug Substance CDMO in Europe by 2026.

• Targeting growth through co-development partnerships, continuous manufacturing, and expanding into high-potential biotech markets, including biosimilars, ADCs, bispecifics, and animal health.

• Recognized with the 2025 International CDMO Leadership Award in Biologics and expanding its client base across Europe, MENA, Asia, and the USA.

Financial performance and position

• Achieved PLN 4.1 million in revenue in Q3 2025, primarily from CDMO services, but revenues remain insufficient to cover operating costs.

• Maintained control over operating costs, with a gross profit margin of 77.1% in Q3 2025; however, net profit remains negative.

• Cash position at the end of Q3 2025 was PLN 4.6 million, requiring additional financing; bridge financing was secured after the balance sheet date.

• Operating cash flow for the first nine months of 2025 was negative at PLN -32.2 million, reflecting ongoing investments and limited capital expenditures.

• Debt remains low, mainly from loans and leasing, with a focus on securing further financing for development.

Business development and growth prospects

• Value of all offers under consideration as of November 2025 reached USD 251 million, with active probability-weighted bids at USD 50.7 million.

• 21 sales processes open as of December 2025, with an average bid value between USD 1-15 million and a 17% success rate on submitted bids since 2023.

• Project pipeline includes qualified leads, NDAs, RFPs, and ongoing negotiations, supporting revenue growth targets of EUR 15-20 million in 2026 and EUR 20-25 million in 2027.

• Strategic focus on expanding service offerings and co-development models to enhance competitiveness and share risks, costs, and profits.

• Operational excellence and process development are key to exceeding financial break-even and achieving sustainable growth.